Greenwich LifeSciences, Inc.
GLSIGreenwich LifeSciences, Inc. (GLSI) is a biopharmaceutical company focused on developing targeted immunotherapies for cancer. The company specializes in advancing innovative treatments, including vaccines designed to stimulate the immune system against specific tumor-associated antigens. Its pipeline primarily targets breast and other solid tumors.
Company News
Greenwich LifeSciences reported delays in filing its Form 10-K for fiscal year 2025 due to coordination issues between dual auditors regarding accounts payable adjustments related to its Phase III FLAMINGO-01 clinical trial. The company maintains a cash balance of approximately $10.5 million as of March 31, 2026, and reported preliminary positive...
Greenwich LifeSciences announced that an abstract presenting preliminary data from its Phase III FLAMINGO-01 trial of GLSI-100 immunotherapy has been accepted for presentation at the 2026 ASCO Annual Meeting (May 28-June 2). The non-HLA-A*02 open-label arm, now fully enrolled with 250 patients, shows approximately 70-80% reduction in breast cance...
Greenwich LifeSciences received a notification from Nasdaq on April 16, 2026, indicating non-compliance with listing rules due to failure to timely file its Annual Report on Form 10-K for fiscal year 2025. The company's stock continues to trade on Nasdaq Capital Market under ticker GLSI with no immediate effect on listing status. The company is w...
Greenwich LifeSciences presented preliminary immune response data from the Phase III FLAMINGO-01 trial of GLSI-100, an immunotherapy for breast cancer recurrence prevention. The non-HLA-A*02 open label arm (247 patients) showed a statistically significant 4-fold increase in delayed-type-hypersensitivity (DTH) immune reactions from 5.2% at baselin...
Greenwich LifeSciences announced new patent claims for GLSI-100 based on Phase III FLAMINGO-01 trial data showing statistically significant immune response and approximately 80% recurrence rate reduction in non-HLA-A*02 breast cancer patients. The claims potentially double the addressable market by an additional 100% (88,000 new patients annually...
